MX2013014708A - Compuestos que inhiben el glioblastoma y su uso. - Google Patents

Compuestos que inhiben el glioblastoma y su uso.

Info

Publication number
MX2013014708A
MX2013014708A MX2013014708A MX2013014708A MX2013014708A MX 2013014708 A MX2013014708 A MX 2013014708A MX 2013014708 A MX2013014708 A MX 2013014708A MX 2013014708 A MX2013014708 A MX 2013014708A MX 2013014708 A MX2013014708 A MX 2013014708A
Authority
MX
Mexico
Prior art keywords
glioblastoma
inhibiting compounds
compounds
treatment
inhibiting
Prior art date
Application number
MX2013014708A
Other languages
English (en)
Other versions
MX340816B (es
Inventor
Björn Scheffler
Martin Glas
Matthias Simon
Sabine Gogolok
Daniel Trageser
Roman Reinartz
Anja Wieland
Original Assignee
Univ Bonn
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Bonn filed Critical Univ Bonn
Publication of MX2013014708A publication Critical patent/MX2013014708A/es
Publication of MX340816B publication Critical patent/MX340816B/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
    • C07D493/12—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains three hetero rings
    • C07D493/20—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
    • C07D493/12—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains three hetero rings
    • C07D493/18—Bridged systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4188—1,3-Diazoles condensed with other heterocyclic ring systems, e.g. biotin, sorbinil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
    • C07D493/02—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
    • C07D493/06—Peri-condensed systems
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • G01N33/57492—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites involving compounds localized on the membrane of tumor or cancer cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/70596—Molecules with a "CD"-designation not provided for elsewhere in G01N2333/705
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Cell Biology (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biotechnology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Microbiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La presente invención se encuentra relacionada a compuestos que inhiben el glioblastoma, en particular a la amida del ácido gambógico y derivados del mismo para el tratamiento del glioblastoma. Más aún, se revelan métodos para determinar si un tratamiento con los compuestos de la invención es adecuado para un paciente.
MX2013014708A 2011-06-15 2012-06-15 Compuestos que inhiben el glioblastoma y su uso. MX340816B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161497215P 2011-06-15 2011-06-15
PCT/EP2012/061485 WO2012172069A1 (en) 2011-06-15 2012-06-15 Glioblastoma inhibiting compounds and their use

Publications (2)

Publication Number Publication Date
MX2013014708A true MX2013014708A (es) 2014-08-18
MX340816B MX340816B (es) 2016-07-26

Family

ID=46319762

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2013014708A MX340816B (es) 2011-06-15 2012-06-15 Compuestos que inhiben el glioblastoma y su uso.

Country Status (13)

Country Link
US (1) US9573960B2 (es)
EP (1) EP2721035B1 (es)
JP (1) JP6228113B2 (es)
CN (1) CN103764659A (es)
AU (1) AU2012268984B2 (es)
BR (1) BR112013032360A2 (es)
CA (1) CA2838945A1 (es)
CL (1) CL2013003563A1 (es)
IL (1) IL229767A0 (es)
MX (1) MX340816B (es)
RU (1) RU2014101070A (es)
WO (1) WO2012172069A1 (es)
ZA (1) ZA201309365B (es)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014023329A1 (en) * 2012-08-06 2014-02-13 Life And Brain Gmbh Niclosamide and its derivatives for use in the treatment of solid tumors
WO2016210289A1 (en) 2015-06-24 2016-12-29 Duke University Chemical modulators of signaling pathways and therapeutic use
EP3328495A4 (en) * 2015-07-31 2019-01-16 Swedish Health Services METHODS AND COMPOSITIONS FOR CHARACTERIZING MULTIPLE-FORM GLIOBLASTOMA TUMORS AND CANCER STEM CELLS
US11499972B2 (en) 2015-09-15 2022-11-15 Swedish Health Services Methods and panels of compounds for characterization of glioblastoma multiforme tumors and cancer stem cells thereof
CN105802928A (zh) * 2016-03-30 2016-07-27 苏州偲聚生物材料有限公司 用于检测血清中mgmt抗体的多肽，检测器件和检测试剂盒
CN105796549A (zh) * 2016-04-22 2016-07-27 中国医学科学院基础医学研究所 藤黄酰胺用于制备治疗人神经胶质瘤的药物的用途
CN107475213A (zh) * 2016-06-08 2017-12-15 中国科学院苏州纳米技术与纳米仿生研究所 用于检测血清中mgmt抗体的多肽，检测器件和检测试剂盒
US11311606B2 (en) 2018-03-13 2022-04-26 Georgetown University Enhancing chemotherapy in medulloblastoma and glioblastoma with high basal p53 levels
CN110433154A (zh) * 2019-08-12 2019-11-12 昆明理工大学 藤黄酸的新用途
WO2023183463A1 (en) * 2022-03-23 2023-09-28 University Of Cincinnati Methods of potentiating temozolomide activity against glioblastoma cells
CN117538458B (zh) * 2024-01-09 2024-03-29 中国医学科学院北京协和医院 同时定量分析14种单糖/二糖的液相色谱串联质谱分析方法

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2864100A (en) * 1999-02-01 2000-08-18 Cytovia, Inc. Methods of identifying therapeutically effective antineoplastic agents with cultured cells having intact cell membranes and corresponding products
US6462041B1 (en) * 1999-05-21 2002-10-08 Cytovia, Inc. Gambogic acid, analogs and derivatives as activators of caspases and inducers of apoptosis
JP3904364B2 (ja) 2000-03-03 2007-04-11 独立行政法人科学技術振興機構 抗マラリア活性を有する新規化合物
EP1300403A1 (en) * 2001-10-02 2003-04-09 Aventis Pharma S.A. Process for the manufacture of hypoxyxylerone derivatives
WO2008148008A1 (en) * 2007-05-23 2008-12-04 Emory University High throughput bioassay for identifying selective trka receptor agonists, and gambogic amide, a selective trka agonist with neuroprotective activity
CN101289482B (zh) * 2007-09-29 2011-08-31 辽宁利锋科技开发有限公司 藤黄酸苷衍生物和类似物及其制备方法和用途
PA8851101A1 (es) * 2008-12-16 2010-07-27 Lilly Co Eli Compuesto amino pirazol

Also Published As

Publication number Publication date
CN103764659A (zh) 2014-04-30
ZA201309365B (en) 2015-11-25
CL2013003563A1 (es) 2014-06-06
RU2014101070A (ru) 2015-07-20
US20150148390A1 (en) 2015-05-28
WO2012172069A1 (en) 2012-12-20
BR112013032360A2 (pt) 2017-06-13
EP2721035B1 (en) 2018-06-13
CA2838945A1 (en) 2012-12-20
JP2014517025A (ja) 2014-07-17
AU2012268984B2 (en) 2016-07-14
EP2721035A1 (en) 2014-04-23
NZ618170A (en) 2015-04-24
MX340816B (es) 2016-07-26
JP6228113B2 (ja) 2017-11-08
US9573960B2 (en) 2017-02-21
IL229767A0 (en) 2014-01-30

Similar Documents

Publication Publication Date Title
MX340816B (es) Compuestos que inhiben el glioblastoma y su uso.
HK1200449A1 (en) Substituted benzylindazoles for use as bub1 kinase inhibitors in the treatment of hyperproliferative diseases bub1
MX2015007921A (es) Compuestos heterociclicos novedosos como inhibidores de bromodominio.
HK1215256A1 (zh) 用作吲哚胺 -二氧化酶的抑制劑的化合物
WO2014080290A3 (en) Cyclic amines as bromodomain inhibitors
MX353482B (es) Metodos para el tratamiento del cancer y enfermedades inflamatorias utilizando cereblon como predictor.
MX2019008122A (es) Derivados de aminas heterociclicas que inhiben la transduccion de se?al mediada por cinasa asociada con el receptor de interleucina-1.
TN2012000578A1 (en) Tetrahydro-pyrido-pyrimidine derivatives
EA201491149A1 (ru) Пиразолопиридиновые производные, способы их получения и их терапевтическое применение
IN2015DN01151A (es)
PH12014501195A1 (en) Novel 2h-indazoles as ep2, receptor antagonists
MX2014003376A (es) Derivados de acido benzoico como inhibidores eif4e.
MX2013008340A (es) Novedosas 4-amino-n-hidroxi-benzamidas para el tratamiento de cancer.
JO3063B1 (ar) مركب مبتكر وطرق لانتاجه
EA201491227A1 (ru) Новые производные морфолинила, подходящие для применения в качестве ингибиторов mogat-2
EP2663193A4 (en) CARBON MONOXIDE SOLUTION FOR THE TREATMENT OF DISEASES, INCLUDING SICKLE LENGTH
TN2013000420A1 (en) 2-amino-3-(imidazol-2-yl)-pyridin-4-one derivatives and their use as vegf receptor kinase inhibitors
EA201391586A1 (ru) ИНГИБИТОРЫ 17α-ГИДРОКСИЛАЗЫ/C-ЛИАЗЫ
PT3135286T (pt) Métodos de utilização de derivados amida cíclica para tratar esquizofrenia e seus sintomas
EP2697239A4 (en) N-SUBSTITUTED MANNOSAMINE DERIVATIVES, PROCESS FOR THEIR PREPARATION AND THEIR USE
EA201590594A1 (ru) Макролидные производные, их получение и их терапевтическое использование
MX2014009084A (es) Derivados de pirimidooxazocina como inhibidores de mtor.
IN2014DN07407A (es)
IL229791A0 (en) Indoleamine derivatives for the treatment of diseases of the central nervous system
MX2013005759A (es) Metodos para detectar bajo grado de inflamacion.

Legal Events

Date Code Title Description
FG Grant or registration